文献速递乳腺癌放疗

ACCEL研究:27 Gy分5次每日加速部分乳腺照射的1年美容效果与纤维化

One-Year Cosmesis and Fibrosis From ACCEL: Accelerated Partial Breast Irradiation (APBI) Using 27 Gy in 5 Daily Fractions.
PubMed 文献 · Pract Radiat Oncol · 2019-04-09

ACCEL是一项前瞻性II期试验,入组保乳术后切缘阴性、基线美容评分为优或良的淋巴结阴性乳腺癌患者,接受27 Gy分5次每日调强放疗。中期分析55例可评估,1年时53%美容改善、40%无变化,仅2例(4%)由优/良降至一般,无毛细血管扩张或2级及以上纤维化,无复发。

要点

  • 27 Gy分5次每日加速部分乳腺照射1年美容可接受,53%改善、40%无变化。
  • 基线优/良的49例中仅2例(4%)1年降为一般,无毛细血管扩张或2级及以上纤维化。
  • 预设5%的2级及以上纤维化停止规则未触发,试验将继续至目标入组274例。

核心结论

  • 27 Gy分5次每日加速部分乳腺照射获得可接受的1年美容效果,无2级纤维化。

研究设计与样本

  • 前瞻性II期试验,入组保乳术后切缘阴性、医生评估基线美容优或良的淋巴结阴性乳腺癌患者,接受27 Gy分5次每日调强放疗至扩大原发灶区。
  • 预设50例完成1年随访时进行中期分析,本次分析55例有基线和放疗后1年图像。
  • 由6名医生组成的小组基于临床照片提供共识整体美容评分(小组评估评分),纤维化和毛细血管扩张由临床研究人员前瞻性评估。

主要发现

  • 从基线至1年,53%患者美容改善、40%无变化。
  • 基线小组评估评分为优或良的49例中,仅2例(4%)在放疗后1年评为一般,提示美容退化。
  • 无患者出现毛细血管扩张或2级及以上纤维化证据,无复发。

关键数值与推荐

  • 放疗剂量为27 Gy分5次每日。
  • 预设2级及以上纤维化5%的停止规则未观察到。
  • 试验将继续至计划目标入组274例。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report 1-year cosmesis and toxicity outcomes of a prospective, phase II trial of accelerated partial breast irradiation using intensity-modulated radiation therapy (RT) to deliver 27 Gy in 5 daily fractions. METHODS AND MATERIALS: Node-negative breast cancer patients after breast conserving surgery with clear excision margins, with physician-assessed excellent or good baseline cosmesis were invited to participate in a prospective clinical trial to receive 27 Gy in 5 daily fractions to the expanded primary site. Clinical photographs and European Organisation for Research and Treatment of Cancer cosmetic score were collected at baseline prior to RT and 1-year after radiation therapy. A protocol-specified, interim analysis was scheduled when 50 patients had completed 1-year follow-up. A panel of 6 physicians provided a consensus global cosmetic score (termed panel-assessed score) based on clinical photographs at baseline and 1-year. Fibrosis and telangiectasia were prospectively assessed by clinical research staff at clinic visits. RESULTS: At the interim analysis, 55 patients had baseline and 1-year post-RT images available. Most patients had either an improvement (53%) or no change (40%) in cosmesis from baseline to 1-year. Among 49 patients with excellent or good panel-assessed score at baseline, only 2 (4%) patients had a fair score at 1-year post-RT, indicating cosmetic deterioration. No patients had evidence of telangiectasia or grade 2 or higher fibrosis. There were no recurrences. CONCLUSIONS: APBI using 27 Gy in 5 daily fractions achieved acceptable 1-year cosmesis and no grade 2 fibrosis. A preplanned stopping rule of 5% grade 2+ fibrosis was not observed. The trial will continue to the planned target accrual of 274 patients.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Grendarova P, Roumeliotis M, Quirk S, et al. One-Year Cosmesis and Fibrosis From ACCEL: Accelerated Partial Breast Irradiation (APBI) Using 27 Gy in 5 Daily Fractions. Pract Radiat Oncol. 2019. PMID: 30978468. doi:10.1016/j.prro.2019.04.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。